Lewy Body Dementia
Oral small molecule shows promise in dementia with Lewy bodies
According to results from the exploratory phase 2 SHIMMER clinical trial, a small molecule oligomer antagonist improved outcomes in patients with dementia with Lewy bodies.
VIDEO: American Brain Foundation funds research in Lewy body dementia, neuroinflammation
DENVER — The American Brain Foundation is funding research to find a cure for Lewy body dementia and discover breakthroughs in neuroinflammation, the group’s executive director said at the American Academy of Neurology annual meeting.
Positive data reported in phase 2 study of treatment for Parkinson’s, Lewy body dementia
A clinical-stage biopharmaceutical company has announced positive findings from the exploratory SHAPE phase 2 clinical trial to evaluate fosgonimeton in those with Parkinson’s disease dementia and dementia with Lewy bodies.
Quetiapine most often prescribed for dementia associated with PD, Lewy bodies
CHICAGO — Quetiapine remains the drug of choice for psychosis in patients with Parkinson’s disease dementia and dementia with Lewy bodies, per data at the International Association of Parkinsonism and Related Disorders World Congress.
Investigational drug for Parkinson’s, Lewy body dementia not successful in phase 2 trial
Biopharmaceutical company Aptinyx reported its drug for cognitive impairment was not efficacious in a phase 2 clinical trial investigating its use in patients with Parkinson’s disease and Lewy body dementia, according to a press release.
NIH awards Cleveland Clinic $10.7M for Lewy body dementia study
The NIH has awarded a $10.7 million 5-year renewal grant to Cleveland Clinic to expand a national research consortium focused on improving the diagnosis and treatments for dementia with Lewy bodies.
Aptinyx completes enrollment of phase 2 trial for oral cognitive impairment treatment
Aptinyx Inc. announced it has completed enrollment in the company’s ongoing phase 2 study of NYX-458, an oral treatment for cognitive impairment associated with Parkinson’s disease and dementia with Lewy bodies.
FDA grants breakthrough designation for Lewy body detection test
Progression of Lewy body dementia can be seen in 6 months
Use of common clinical instruments helped identify progression of Lewy body dementia clinical features like global cognition and parkinsonism during a 6-month observation period, according to findings published in Neurology.